Perampanel, a novel, non-competitive, selective AMPA receptor antagonist as adjunctive therapy for treatment-resistant partial-onset seizures

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 2, 2013, Pages 225-235

  Rektor, Ivan ^a  

^a ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

Author keywords

AMPA receptor antagonist; Anticonvulsant agent; Partial onset seizures; Perampanel; Refractory epilepsy

Indexed keywords

AMPA RECEPTOR; CARBAMAZEPINE; ETIRACETAM; LAMOTRIGINE; PERAMPANEL; PHENYTOIN; PLACEBO; TOPIRAMATE; VALPROIC ACID;

ADJUVANT THERAPY; ADVERSE OUTCOME; ARTICLE; ATAXIA; DIARRHEA; DIZZINESS; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EPILEPSY; FALLING; FATIGUE; HEADACHE; HUMAN; IRRITABILITY; NONHUMAN; RHINITIS; SEIZURE; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE;

ANIMALS; ANTICONVULSANTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; EPILEPSIES, PARTIAL; HUMANS; MOLECULAR TARGETED THERAPY; PYRIDONES; RECEPTORS, AMPA; TREATMENT OUTCOME;

EID: 84872706011     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.754883     Document Type: Article

References (34)

1. World Health Organization. Epilepsy Fact Sheet No 999. Available from: http://www.who.int/mediacentre/factsheets/fs999/en/index.html [Last accessed 29 March 2012]
2. Perucca E, French J, Bialer M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6:793-804
3. French JA. Refractory epilepsy: clinical overview. Epilepsia 2007;48(Suppl 1):3-7
4. Schmidt D. The clinical impact of new antiepileptic drugs after a decade of use in epilepsy. Epilepsy Res 2002;50:21-32
5. Krakow K, Walker M, Otoul C, Sander JW. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001;56:1772-4
6. Lhatoo SD, Wong IC, Polizzi G, Sander JW. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000;41:1592-6
7. National Institute for Health and Clinical Excellence. The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 137. Available from: http://www.nice.org.uk/nicemedia/live/13635/57779/57779.pdf [Last accessed 31 July 2012]
8. Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol 2011;10:446-56
9. Bialer M, White HS. Key factors in the discovery and development of new antiepileptic drugs. Nat Rev Drug Discov 2010;9:68-82
10. Chappell AS, Sander JW, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology 2002;58:1680-2
11. Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single-and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia 2003;44:46-53
12. Hanada T, Hashizume Y, Tokuhara N, et al. Perampanel: a novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 2011;52:1331-40
13. Templeton D. Pharmacokinetics of perampanel, a highly selective AMPA-type glutamate receptor antagonist. Epilepsia 2009;50(Suppl 11):abstract 1.199
14. Rogawski MA. Revisiting AMPA receptors as an antiepileptic drug target. Epilepsy Curr 2011;11:56-63
15. Tokuhara N, Hatakeyama S, Amino H, et al. Pharmacological profile of perampanel: a novel, non-competitive selective AMPA receptor antagonist. Abstract P02.112 presented at the 60th Annual Meeting of the American Academy of Neurology; 12-19 April 2008; Chicago, IL, USA
16. Ceolin L, Bortolotto Z, Bannister N, et al. A novel anti-epileptic agent, perampanel, selectively inhibits AMPA receptor-mediated synaptic transmission in the hippocampus. Neurochem Int 2012;61:517-22
17. Balannik V, Menniti FS, Paternain AV, et al. Molecular mechanism of AMPA receptor noncompetitive antagonism. Neuron 2005;48:279-88
18. Sobolevsky AI, Rosconi MP, Gouaux E. X-ray structure, symmetry and mechanism of an AMPA-subtype glutamate receptor. Nature 2009;462:745-56
19. Barton ME, Klein BD, Wolf HH, White HS. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res 2001;47:217-27
20. Fuseau E, Templeton D, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel in patients with refractory partial seizures. Epilepsy Curr 2011;11(Suppl 1):abstract 1.264
21. Laurenza A, Ferry J, Hussein Z. Population pharmacokinetics and pharmacodynamics of perampanel: a pooled analysis from three phase III trials. Epilepsy Curr 2012;12(Suppl 1):abstract 2.231
22. Krauss GL, Bar M, Biton V, et al. Tolerability and safety of perampanel: two randomized dose-escalation studies. Acta Neurol Scand 2012;125:8-15
23. Krauss GL, Serratosa JM, Villanueva V, et al. Randomized phase III study 306: adjunctive perampanel for refractory partial-onset seizures. Neurology 2012;78:1408-15
24. French J, Krauss GL, Biton V, et al. Adjunctive perampanel for refractory partial-onset seizures: randomized Phase III study 304. Neurology 2012;79:589-96
25. French JA, Krauss GL, Steinhoff BJ, et al. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global Phase III study 305. Epilepsia 2012; Epub ahead of print
26. Kramer L, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: a dose-response analysis from Phase III studies. Neurology 2012;78(Suppl 1):abstract P06.117
27. Rektor I, Krauss GL, Bar M, et al. Perampanel study 207: long-term openlabel evaluation in patients with epilepsy. Acta Neurol Scand 2012;126:263-9
28. Krauss GL, Perucca E, Ben-Menachem E, et al. Perampanel, a selective, noncompetitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III extension study 307. Epilepsia 2012; Epub ahead of print
29. St Louis EK. Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care. Curr Neuropharmacol 2009;7:106-14
30. French J, Elger C, Goldberg-Stern H, et al. Use of perampanel, a selective, non-competitive AMPA receptor antagonist, as adjunctive therapy in patients with refractory partial-onset seizures: results of a global phase III study. Abstract 020 presented at the 29th International Epilepsy Congress; 1 September-28 August 2011; Rome, Italy
31. Hussein Z, Ferry J, Krauss G.L, et al. Demographic factors and concomitant antiepileptic drugs have no effects on the pharmacodynamics of perampanel. Poster presented at the 64th American Academy of Neurology Annual Meeting; 21-28 April 2012; New Orleans, LA, USA
32. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-19
33. Meldrum BS, Rogawski MA. Molecular targets for antiepileptic drug development. Neurotherapeutics 2007;4:18-61
34. Lees GJ. Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders. Drugs 2000;59:33-78